Skin lesions in chronic myeloid leukemia patients during dasatinib treatment

References

• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–3127. doi:10.1002/cncr.2652322294282
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884. doi:10.1182/blood-2012-12-47102923803709
   PubMed Web of Science ®Google Scholar
• Rea D, Cayuela JM. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;108:355–364. doi:10.1007/s12185-017-2295-028689264
   PubMed Web of Science ®Google Scholar
• Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015;94(Suppl 2):S149–S158. doi:10.1007/s00277-015-2318-y25814081
   PubMedGoogle Scholar
• Russo Rossi A, Breccia M, Abruzzese E, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 2013;98:399–403. doi:10.3324/haematol.2012.06433722801965
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671. doi:10.1038/leu.2016.10427121688
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–2270. doi:10.1056/NEJMoa100231520525995
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol. 2013;27:1471–1480. doi:10.1111/jdv.1217223611501
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2013;24:386–395. doi:10.1111/j.1529-8019.2011.01431.x
   Web of Science ®Google Scholar
• Bergman JC, Ly TY, Keating MM, et al. Recurrent and fixed neutrophilic dermatosis associated with dasatinib. J Cutan Med Surg. 2018;22:621–623. doi:10.1177/120347541877566329754527
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Ilander M, Porkka K, et al. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. OncoImmunology. 2014;3:e28925. doi:10.4161/onci.2892525083322
   PubMed Web of Science ®Google Scholar
• Iriyama N, Fujisawa S, Yoshida C, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol. 2015;90:819–824. doi:10.1002/ajh.2409626103598
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772–782. doi:10.1182/blood-2009-12-25680020413659
   PubMed Web of Science ®Google Scholar
• Zagaria A, Anelli L, Albano F, et al. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2006;167:97–102. doi:10.1016/j.cancergencyto.2006.01.01116737907
   PubMed Web of Science ®Google Scholar
• Albano F, Anelli L, Zagaria A, et al. “Home-brew” FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;174:121–126. doi:10.1016/j.cancergencyto.2006.09.02517452253
   PubMedGoogle Scholar
• Albano F, Anelli L, Zagaria A, et al. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer. 2010;9:120. doi:10.1186/1476-4598-9-12020500819
   PubMed Web of Science ®Google Scholar
• Albano F, Anelli L, Zagaria A, et al. Decreased TET2 gene expression during chronic myeloid leukemia progression. Leuk Res. 2011;35:e220–e222. doi:10.1016/j.leukres.2011.07.01321794915
   PubMed Web of Science ®Google Scholar
• Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003. doi:10.1038/leu.2015.2925652737
   PubMed Web of Science ®Google Scholar
• Cross NC, White HE, Ernst T, et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016;30:1844–1852. doi:10.1038/leu.2016.9027109508
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi:10.1056/NEJMicm02003712637609
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386–395. doi:10.1111/j.1529-8019.2011.01431.x21910796
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259. doi:10.1056/NEJMoa091261420525993
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–4576. doi:10.1182/blood-2011-02-33487021865346
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796. doi:10.1056/NEJMoa130649424180494
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. Cancer. 2016;122:1398–1407. doi:10.1002/cncr.2993326998677
   PubMed Web of Science ®Google Scholar
• Qiu Z-Y, Xu W, Li. J-Y. Large granular lymphocytosis during dasatinib therapy. Cancer Biology & Therapy. 2014;15:247–255. doi:10.4161/cbt.2731024352048
   PubMed Web of Science ®Google Scholar